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Abstract
Background: Mortality from acute myocardial infarction (AMI) is declining worldwide. We sought to determine
if mortality in the Veterans Health Administration (VHA) has also been declining.
Methods: We calculated 30-day mortality rates between 2004 and 2006 using data from the VHA External Peer
Review Program (EPRP), which entails detailed abstraction of records of all patients with AMI. To compare trends
within VHA with other systems of care, we estimated relative mortality rates between 2000 and 2005 for all males
65 years and older with a primary diagnosis of AMI using administrative data from the VHA Patient Treatment
File and the Medicare Provider Analysis and Review (MedPAR) files.
Results: Using EPRP data on 11,609 patients, we observed a statistically significant decline in adjusted 30-day
mortality following AMI in VHA from 16.3% in 2004 to 13.9% in 2006, a relative decrease of 15% and a decrease
in the odds of dying of 10% per year (p = .011). Similar declines were found for in-hospital and 90-day mortality.
Based on administrative data on 27,494 VHA patients age 65 years and older and 789,400 Medicare patients, 30-
day mortality following AMI declined from 16.0% during 2000-2001 to 15.7% during 2004-June 2005 in VHA and
from 16.7% to 15.5% in private sector hospitals. After adjusting for patient characteristics and hospital effects, the
overall relative odds of death were similar for VHA and Medicare (odds ratio 1.02, 95% C.I. 0.96-1.08).
Conclusion: Mortality following AMI within VHA has declined significantly since 2003 at a rate that parallels that
in Medicare-funded hospitals.
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Background
The Department of Veterans Affairs (VA) operates the larg-
est integrated health care system in the U.S. including 154
medical centers in all 50 states and Puerto Rico. Over the
past 12 years the Veterans Health Administration (VHA)
has undergone a remarkable transformation accompanied
by remarkable improvements in quality. [1] In a study of
nearly 600 patients receiving care from VHA in 12 com-
munities between 1997 and 2000, their health care was
generally of higher quality on 294 measures than that
received by nearly 1000 patients enrolled in commercial
managed care plans in the same communities.[2] More
recently, VHA's performance on a wide range of measures
that are monitored for patients enrolled in Medicare,
Medicaid, and commercial managed care plans (Health
Employer Data Set - HEDIS) outpaced that of health care
plans in these settings. [3] On most of the ORYX measures
publicly reported by The Joint Commission, VHA's most
recent average national scores equaled or exceeded mean
scores for non-VA facilities.[4] These achievements
reflected by performance measures are paralleled by data
indicating that adjusted mortality was lower over a four-
year period for patients receiving care in VHA compared
with those enrolled in the Medicare Advantage program.
[5] These efforts have led to VHA's recognition as one of
the highest quality health care systems in the nation [6-9],
although others have questioned their validity. [10]
In the area of cardiac care, studies performed a decade ago
found that mortality following acute myocardial infarc-
tion (AMI) among patients treated in VHA facilities was
similar to that of patients whose care was funded by Medi-
care in non-VA hospitals. [11,12] Subsequently, in an
external study commissioned by VA that used administra-
tive data from patients hospitalized with AMI between
1996 and 1999, Landrum and colleagues found that sur-
vival was significantly lower at one year than for patients
whose care was funded by Medicare. [13] Despite con-
cerns about that study's methodology, VA used the study
as an impetus for an ambitious 10-point cardiac care ini-
tiative intended to improve acute cardiac care.[14]
A subsequent study, however, showed that the higher
mortality within VHA reported by Landrum, et al was
likely an artifact related to a much higher proportion of
patients who suffered an AMI after being admitted to the
hospital for another medical problem in the VA system
than in the Medicare cohorts. [15] Given these controver-
sies, we sought to reevaluate trends in mortality since the
VA cardiac care initiative was undertaken. Moreover,
because mortality related to cardiac disease has been
declining worldwide, we also were interested in compar-
ing trends within VHA with the Medicare population as an
indication of secular trends. [16]
Methods
We undertook two separate sets of analyses: one to calcu-
late annual mortality rates in VHA following AMI and a
second to compare mortality rates among patients treated
for AMI in VHA hospitals and those in hospitals funded
by Medicare (Table 1).
Trends in Mortality in VHA
To examine trends in mortality following AMI within
VHA we used information from the VHA External Peer
Review Program (EPRP), which is a quality monitoring
and improvement system for a variety of medical condi-
tions and procedures, including AMI. All patients who
were age 65 years and older and who had been assigned
International Classification of Diseases, 9th Revision: Clinical
Table 1: Description of studies performed
Study and Comparisons
Trends in AMI mortality within VHA Trends in AMI mortality within VHA and Medicare
Time Period 1/1/2004 - 9/30/2006 1/1/2000 - 6/30/2005
Study sample All patients ≥65 years old with ICD-9-CM codes 
410.xx
All patients ≥65 years old with ICD-9-CM codes 410 except 
410.x2
Sample size 11,609 patients 27,494 VHA patients and 789,400 Medicare patients
789,400 Medicare patients
Data Sources
Identification of patients Abstracted record of all patients with AMI 
(External Peer Review Program)
VA Patient Treatment File (PTF); Medicare Provider Analysis and 
Review (MedPAR) File Provider Analysis and Review (MedPAR) 
File
Mortality VA Vital Status File MedPAR; VA Vital Status FileBMC Cardiovascular Disorders 2009, 9:44 http://www.biomedcentral.com/1471-2261/9/44
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Modification (ICD-9-CM), diagnostic codes 410.xx at 145
VHA hospitals during the period January 1, 2004 through
September 30, 2006 were identified from administrative
data housed at the Austin Automation Center, Austin, TX.
Trained abstractors under contract to the EPRP program
reviewed these records to validate the coded diagnoses
and collect extensive clinical information. We used infor-
mation from EPRP and VA workload files to describe
demographic and personal characteristics (e.g., age, sex,
ethnicity, body mass index and distance from the vet-
eran's residence to the medical center), receipt of reper-
fusion therapy, and use of cardiac procedures. [17,18]
Ethnicity was classified as African-American, Hispanic,
White, other, or unknown. Clinical data, such as medical
history, cardiac medications administered, time from
symptom onset to hospital admission, initial heart rate,
systolic and diastolic blood pressures, and initial symp-
toms, were obtained from the medical record. Patients
included in the analysis were males age 65 or older who
presented to a VHA facility with an AMI. Patients who
developed evidence of AMI during hospitalization were
excluded.
The initial electrocardiographic diagnosis of ST-segment
elevation AMI included patients with ST-segment eleva-
tion of 1 mV or higher in 2 or more contiguous leads and/
or left bundle branch block. The remainder of patients
had non-ST-segment elevation AMI. Both the initial and
highest troponin values were recorded; positive tests were
determined according to criteria for the particular assay
used. In both groups, more than 99% of the AMIs were
confirmed by troponin level elevations.
Ascertainment of Vital Status
The primary endpoint was all-cause mortality within 30
days of admission. Secondary endpoints were in-hospital,
90-day, and 1-year mortality. Vital status was ascertained
using the VA vital status file, which melds four separate
sources: VA Beneficiary Identification and Record Locator
System (BIRLS); VA Patient Treatment File (PTF); Social
Security Administration death master file; and Medicare
vital status file. The VA vital status file has been shown to
have a sensitivity of 98.3% and specificity was 99.8% in
comparison with the National Death Index. [19]
Analysis
We applied a logistic regression model for 30-day mortal-
ity that was developed and validated expressly for VA
patients using earlier versions of EPRP data. [15] The
model includes history of cancer, history of dementia, his-
tory of heart failure, history of stroke within 5 years, his-
tory of lipid disorder or prescriptions for lipid
medications, age, elevated initial troponin, creatinine,
heart rate, systolic blood pressure, chest and/or shoulder
pain, and presentation at night. Analyses were run with
and without a cluster correction for medical center.
Comparisons of Trends in VHA with Medicare
We used comparable administrative data to estimate the
relative mortality rates among patients admitted with AMI
to VHA medical centers versus patients whose care was
covered by Medicare at non-VA hospitals. Data were
derived from two primary sources: the Medicare Provider
Analysis and Review (MedPAR) data files; and the VA
Patient Treatment File. The MedPAR files contain admin-
istrative data on all Medicare fee-for-service hospitaliza-
tions, including: demographic information; admission
source (e.g., transfer from another hospital, emergency
room); ZIP code; primary and secondary diagnoses and
procedures, as defined by ICD-9-CM codes; hospital
admission and discharge dates; disposition at the time of
hospital discharge; and a six-digit unique hospital identi-
fier. The MedPAR files are matched quarterly to the Medi-
care Enrollment database to incorporate dates of death
after hospital discharge. The Patient Treatment File con-
tains data on all hospitalizations in VA medical centers
nationally and includes similar data elements as the Med-
PAR files. The US Census 2000 Summary File was the
source for ZIP code-level socioeconomic measures (e.g.,
median household income). In order to identify non-VA
hospitals in the same geographic markets as VA hospitals,
we used the Dartmouth Atlas to map each VA and non-VA
hospital to one of 306 distinct hospital referral regions
(i.e., health care markets) for tertiary health services.
[20,21]
Patients
VA patients were comprised of all males 65 years and
older with a primary diagnosis of AMI (ICD-9-CM code
410, excluding 410.x2) who were admitted between Janu-
ary 1, 2000 and June 30, 2005 to 145 VA hospitals (n =
33,632). Medicare patients were similarly defined and
included 4,580 non-VA hospitals (n = 955,780), with
2,876 hospitals located in 112 geographic markets with a
VA hospital. We limited the analysis to males, given the
preponderance of males (98.5%) in the VA sample. We
further excluded 146,953 (14.8%) patients who were
admitted as transfers from other acute care hospitals and
25,565 (2.6%) patients who could not be matched to ZIP
code-level socioeconomic measures.
The analysis incorporated a variety of characteristics
including demographic variables such as age, ethnic
group (categorized as White, Black, Hispanic, other, or
missing), median household income (based on residen-
tial ZIP code-level data), admission from a skilled nursing
facility, and distance from the patient's residence to the
admitting hospital (based on distance between ZIP code
centroids). Clinical variables included coexisting condi-
tions listed in Table 4 (defined by ICD-9-CM secondary
diagnosis codes using previously defined algorithms for
administrative data developed by Elixhauser, et al [22]
and Hannan, et al [23]; and type of AMI (categorized asBMC Cardiovascular Disorders 2009, 9:44 http://www.biomedcentral.com/1471-2261/9/44
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anterior or lateral, inferior or posterior, subendocardial,
or other unspecified location (defined by the fourth digit
of the primary ICD-9-CM code)).
Ascertainment of Vital Status
Mortality after 30 days among patients treated within
VHA was established using the VA Vital Status File, while
mortality of Medicare patients was determined using the
date of death recorded in Medicare enrollment files.
Analysis
Characteristics of patients that were related on a bivariate
basis (p < .01) to each of the mortality endpoints were
entered into stepwise logistic regression models. We elim-
inated predictors that were not significant (p ≥ .01) or
which exhibited effects that were not parsimonious with
expected clinical effects. Remaining predictors were
entered into subsequent logistic regression models that
also included discharge year (categorized as 2000-2001,
2002-2003, and 2004-June 2005) and an indicator varia-
ble for admission to a VA hospital. Models included ran-
dom intercepts for hospitals. Thus, the exponentiated
value of the VA hospital indicator represents the odds of
death in the "average" VA hospital relative to the "aver-
age" private sector hospital. Models were also generated
separately for patients discharged during 2000-2001,
2002-2003, and 2004-June 2005. Finally, analyses were
conducted for all patients nationwide and for patients
who were admitted to the 112 hospital referral regions
that included VA hospitals.
SPSS version 13.0, SAS 9.0, and Stata version 9.0 statistical
software (SPSS Inc, Chicago, IL, and StataCorp, College
Station, TX, respectively) were used for all analyses
reported. This study was approved by the Institutional
Review Boards of the University of Washington, Seattle,
and University of Iowa, Iowa City, and waivers of
informed consent were granted.
Results
Trends in Mortality in VHA
Based upon VA EPRP data, there were a total of 11,609
patients with AMI available for analysis including 4411 in
2004, 4412 in 2005 and 2786 in 2006. The mean age was
76.9 years (Table 2). Over half the patients were White,
but sizable proportions were African-American (9.4%) or
Hispanic (6.9%) while ethnic classification was unknown
in 25.3%. There was a high prevalence of preexisting car-
diac disease as evidenced by the fact that one-quarter of
patients had a prior history of AMI, one-third carried a
diagnosis of heart failure, and nearly one-quarter had
undergone coronary artery bypass surgery. Most patients
had multiple cardiac risk factors including lipid abnor-
malities (64.3%), smoking (13.5%) and diabetes
(63.4%). Many patients were receiving cardioprotective
medications such as aspirin, β-blockers, angiotensin-con-
verting enzyme inhibitors or lipid-lowering drugs at the
time of admission.
Using detailed clinical data to adjust for demographic and
clinical factors, we observed a statistically significant
decline in 30-day mortality following AMI from 16.3% in
2004 to 13.9% in 2006, a relative decrease of 15% and a
decrease in the odds of dying of 10% per year (p = .011,
Table 3 and Figure 1). Similar declines were found for in-
hospital and 90-day mortality.
Comparisons of Trends in VHA with Medicare
Declines in mortality following AMI within VHA hospitals
were compared with those experienced in private sector
hospitals using administrative data from VHA and CMS.
Table 2: Characteristics of Patients with AMI treated in VHA
Mean age, mean ± SD, y 76.9 ± 6.9
Age, %
65-69 y 16.9
70-79 y 46.1
80-89 y 34.1
>90 y 2.9
Ethnicity, %
Hispanic 6.9
African American 9.4
White 57.8
Other 0.6
Unknown 25.3
Distance from home to hospital in miles, mean ± SD 39 ± 117
Geographic region of medical center, %
New England 3.2
Mid-Atlantic 10.0
Great Lakes 10.6
North Plants 8.7
South Atlantic (including Puerto Rico) 28.3
Mississippi 7.7
South Plains 11.5
Great Basin 9.5
Pacific 10.6
Medical history, %
Myocardial infarction 26.5
Lipid disorder 64.3
Coronary angioplasty/PCI w/in 6 mos 3.5
Coronary artery bypass surgery 23.8
Heart failure 37.7
Diabetes mellitus 63.4
Renal disease 18.6
Cerebrovascular disease 9.6
Chronic obstructive pulmonary disease 21.7
Dementia 16.3
Cancer 11.5
Current smoking 13.5
Medications at the time of admission for AMI, %
Aspirin 49.8
Beta-blocker 57.3
Angiotensin-converting enzyme inhibitor 48.4
Lipid-lowering drug 54.9
Insulin 15.6
2004-2006 (n = 11,609)BMC Cardiovascular Disorders 2009, 9:44 http://www.biomedcentral.com/1471-2261/9/44
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The final sample included 27,494 patients age 65 years
and older admitted to VHA medical centers, and 789,400
Medicare patients admitted to private sector hospitals for
AMI during the period 2000 to June 2005, with 500,796
(63.4%) Medicare patients in hospitals in the same geo-
graphic region as a VA Hospital.
VHA patients were on average a year and one-half younger
than private sector Medicare patients (mean ages 75.7 vs.
77.1, Table 4), were less apt to be White, and had a sub-
stantially lower median annual income. Patients admitted
to VHA hospitals were more likely to have previous diag-
noses of cerebrovascular disease, COPD, diabetes, liver
disease, depression, or hypertension while Medicare
patients were more likely to have cardiac arrhythmia, kid-
ney or heart failure, or neurologic disorder. AMIs in
patients in the Medicare cohort were more likely to be in
anterior/lateral or inferior/posterior locations while AMIs
in the VA cohort were more likely to classified as subendo-
cardial or "other."
For the period January 1, 2000 through June 30, 2005,
overall unadjusted 30-day mortality was 16.0% in VHA
hospitals and 16.2% in private sector hospitals (Table 5).
Mortality declined in both cohorts, from 16.7% during
2000-2001 to 15.5% during 2004-June 2005 for private
sector hospitals, and from 16.0% to 15.7% during that
same period for VHA hospitals. After adjusting for patient
characteristics and hospital effects, the overall relative
odds of death were not significantly different for VHA or
private sector hospitals (odds ratio 1.02, 95% 0.96-1.08,
Table 6). Moreover, we observed no differences in analy-
ses conducted separately using patients discharged during
2000-2001, 2002-2003, and 2004-June 2005, or when we
restricted analyses to hospitals located within a market
that contains a VHA hospital.
Discussion
Using both administrative data and detailed clinical infor-
mation abstracted from medical records, we found that
mortality following AMI among patients admitted to VA
medical centers significantly declined between 2004 and
2006. This decline approximates the decrease that has
occurred in hospitals outside of the VHA system during
the same timeframe. These results are consistent with
reports from a decade ago indicating parity in AMI mortal-
ity between VHA and Medicare. Our findings appear to lay
to rest concerns that were raised more recently that mor-
tality among patients treated for AMI in VHA appeared
significantly higher than for patients whose care was
funded by Medicare. In that study, which was actually
commissioned and funded by VHA, administrative data
from 1997 and 1998 were analyzed to evaluate mortality
for patients admitted with AMI. The investigators reported
that 30-day mortality in the 1997 cohort was 18.4% in VA
and 14.9% in Medicare while figures for one-year mortal-
ity were 34.5% and 28.0% respectively. The gap was
reported to narrow somewhat in 1998 with 30-day mor-
tality estimates of 16.3% and 14.8% for VHA and Medi-
care, respectively, and one-year estimates of 34.0% and
28.7%.
A subsequent study, however, indicated that findings of
high post-AMI mortality in VA patients were biased,
because patients who suffered an AMI after being admit-
ted to the hospital for another problem were far more
Table 3: Adjusted mortality following AMI in VHA
2004 2005 2006 Overall
Obs Pre Adj Obs Pre Adj Obs Pre Adj Obs
In-hospital 0.110 0.099 0.112 0.102 0.103 0.099 0.084 0.099 0.085 0.101
30-day 0.160 0.150 0.163 0.153 0.155 0.151 0.138 0.151 0.139 0.152
90-day 0.237 0.224 0.240 0.228 0.230 0.225 0.209 0.225 0.211 0.227
One-year 0.365 0.354 0.370 0.352 0.362 0.349 NA NA NA 0.359
*Adjustments made for age, heart rate, systolic pressure, persistent chest pain, hyperlipidemia, serum creatinine, elevation of initial troponin 
determination, medical history (heart failure, dementia, cancer or stroke within the past 5 years), and presentation at night. Adjusted mortality is 
Observed/Predicted * overall mortality for each measure. NA = not available, Obs = observed, Pre = predicted.
2004 through 2006* (N = 11,609)
Adjusted mortality with 95% confidence intervals following  AMI in VHA 2004 through 2006 (N = 11,609) Figure 1
Adjusted mortality with 95% confidence intervals fol-
lowing AMI in VHA 2004 through 2006 (N = 11,609).BMC Cardiovascular Disorders 2009, 9:44 http://www.biomedcentral.com/1471-2261/9/44
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prevalent in the VHA than in Medicare cohorts. Using
updated data and methods in previous work, we have
found that in-hospital AMI accounts for 11% of all AMIs
within the VHA system and the mortality for this problem
is 28%, nearly fourfold higher than for patients who are
admitted initially for an evolving AMI. [15] When all
patients with in-hospital AMI were excluded from consid-
eration, 30-day mortality following AMI was found to be
11.9%, which is lower than observed in the present anal-
ysis but includes patients younger than age 65.
Although the decrease in mortality within VA was com-
mensurate with that occurring in the rest of the country, it
may, in part, have been related to an aggressive effort
undertaken within VHA over the past four years. Follow-
ing public release of the data by Landrum, et al, VHA
embarked upon a system-wide cardiac care initiative that
encompassed educational programs for patients and pro-
viders, expansion of performance measurement and qual-
ity improvement systems, creation of administrative
structures to coordinate care for AMI, and enhancement of
Table 4: Characteristics of male VHA and Medicare patients
VHA Medicare
Total no. of patients 27,494 789,400
Mean age, yrs (s.d.) 75.7 (6.4) 77.1 (7.7)
Age 65-69, % 20.1 19.7
Age 70-74, % 24.6 20.9
Age75-79, % 26.7 21.9
Age 80-84, % 19.6 18.9
Age 85-89, % 7.1 12.2
Age 90 plus, % 1.9 6.4
White, % 69.4 89.9
Median income (/$10,000) for ZIP code (s.d.) 37.1 (13.3) 42.5 (15.7)
Distance to admitting facility 32.2 (55.6) 31.7 (61.5)
Admission from extended care facility, % 4.0 0.7
Coexisting Conditions, %
Cardiac Arrhythmia 22.7 31.2
Paralysis 0.7 0.4
Neurological Disorder 4.0 5.4
Coagulation Disorder 2.4 3.3
Weight Loss 1.4 1.1
Psychosis 2.1 0.9
Renal Failure 8.6 9.2
Chronic Heart failure 33.3 39.9
Cerebrovascular disease 8.3 6.7
Chronic obstructive lung disease 25.7 24.4
Liver Disease 0.8 0.5
Depression 3.2 2.0
Diabetes 37.1 27.3
Diabetes with complication 5.4 3.8
Hypertension 53.8 43.4
Location of AMI,%
Anterior/Lateral 8.6 13.9
Inferior/Posterior 10.1 16.3
Subendocardial 59.1 57.9
Other Site 22.1 11.9
Year of Discharge
2000 17.9 18.8
2001 19.1 18.8
2002 18.9 18.8
2003 17.8 18.3
2004 17.3 16.8
2005 (Through June) 9.1 8.4
aged 65 years or older admitted with AMI, June 2000 through June 2005*BMC Cardiovascular Disorders 2009, 9:44 http://www.biomedcentral.com/1471-2261/9/44
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infrastructure such as cardiac catheterization laborato-
ries.[14] There are, however, other explanations as well.
The most likely is that VHA has maintained very high lev-
els of performance with regard to prescribing cardiopro-
tective medications post-AMI. Data from 2006 showed
that eligible patients in VHA received aspirin, statins, and
β-blockers at discharge at least 95% of the time, and that
87% of those with left-ventricular ejection fractions below
40% received angiotensin converting enzyme inhibitors.
These figures exceeded performance of all hospitals
reporting to the Joint Commission.[4] Moreover, investi-
gators have found that VA patients tend to be substantially
more adherent to these medication regimens over time,
presumably because their cost of medications is so much
lower than that of most patients enrolled in Medicare.[24]
There have been concerns that patients in VA were less
likely to undergo indicated cardiac interventions after
AMI. [25] In 2005, 39% of eligible patients with AMI
received thrombolytic therapy within 30 minutes (39%),
which is comparable to all hospitals reporting to the Joint
Commission. However, VA currently reports a lower pro-
portion of patients who undergo percutaneous coronary
interventions within 90 minutes when indicated (48% vs.
78%). Although this latter difference is clinically impor-
tant, it would be likely to translate into only very small
differences in overall survival following AMI. Less than
one-quarter of patients admitted to VA hospitals with AMI
have ST-segment elevation, and of these, only a relatively
small fraction present early enough to be eligible for
emergent PCI. Compared with noninvasive treatment,
emergent PCI improves short-term mortality by approxi-
mately 2% in absolute terms. [26,27] Moreover, Ford, et
al estimate that pharmacologic interventions and rehabil-
itation during and after hospitalization are responsible for
93% of the reduction in mortality following AMI while
only 7% is attributable to revascularization. [28] More
aggressive early treatment of AMI thus is likely responsible
for only a relatively small proportion of the observed
declines in mortality in either VA or Medicare patients.
It could be argued that some of the observed decline in
mortality is simply due to increasing use of "super-sensi-
tive" troponin assays. These assays could be responsible
for increasing detection of patients with minimal myocar-
dial damage whose prognosis is good. However, the data
are inconsistent with this hypothesis. Existing evidence
suggests that elevated troponin, even in the absence of
classic indicators of AMI, confers a substantially increased
risk of short-term mortality so that including these
patients would not necessarily bias mortality downward.
[29] Furthermore, increasing the detection of NSTEMI
AMIs would be expected to increase the proportion of
AMIs that are NSTEMI and to increase the overall number
of AMIs. In the data reported here, the proportion of AMIs
that were NSTEMI increased only slightly from 73% to
Table 5: Unadjusted 30-day mortality rates
Patients in 145 VHA 
hospitals
Medicare patients in 
4580 private sector 
hospitals
Medicare patients in 2876 
hospitals in 112 Markets 
withVHA
Discharge Year N Mortality N Mortality N Mortality
2000-2001 10,165 16.0% 297,121 16.7% 179,279
179,279
16.8%
2002-2003 10,088 16.3% 292,833 16.2% 175,443 16.3%
2004-June 2005 7,241 15.7% 199,446 15.5% 118,580 15.6%
All years 27,494 16.0% 789,400 16.2% 473,302 16.3%
Following admission for AMI in VHA and Medicare, 2000-2005
Table 6: Adjusted odds of death
Odds Ratio (95% CI, p-value)
Discharge Period Relative to Private Sector Hospitals
in all markets
Relative to Private Sector hospitals in 112 markets with VHA
2000-June 2005 1.02 (0.96-1.08; p = .60) 1.01 (0.95-1.07; p = .71)
2000-2001 1.00 (0.92-1.08; p = .91) 1.00 (0.93-1.08; p = .91)
2002-2003 1.05 (0.98-1.13; p = .15) 1.05 (0.97-1.12; p = .18)
2004-June 2005 1.08 (0.98-1.19; p = .10) 1.07 (0.97-1;18; p = .14)
Within 30 days following AMI in VHA hospitals relative to all private sector hospitals and relative to private sector hospitals in markets with a VHA 
hospital: January 1, 2000-June 30, 2005.BMC Cardiovascular Disorders 2009, 9:44 http://www.biomedcentral.com/1471-2261/9/44
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76% while the absolute number of AMIs actually
declined.
To determine whether the observed declines could be
explained by increasing inclusion of patients with small,
low-risk infarcts diagnosed by slight elevations of serum
troponin, we performed a regression of troponin level on
discharge date. Approximately 200 assay type/hospital
groups were excluded because there were less than three
measurements, leaving approximately 9000 of 11,000 tro-
ponin values for analysis. Although we obtained a regres-
sion coefficient of about -0.07 per year (p < 0.0001) for
initial and peak troponins, the R2 was quite small (0.003).
And finally, we performed an informal analysis of 9000
troponin values in an attempt to ascertain whether there
was a trend toward lower values over time. Although the
analysis was complicated by the fact that patients varied
widely with respect to the number of tests performed and
their timing, date of discharge accounted for only 0.3% of
the variance in mean initial and peak troponin levels.
This study has several strengths that include eligibility of
all patients diagnosed with AMI in both VA and Medicare
populations over a period of several years and careful
adjustment of mortality within VHA using two completely
different approaches. In addition, we ascertained mortal-
ity using methods that have been shown to be highly reli-
able and valid. There are, however, significant potential
limitations that deserve comment. First, the EPRP data
used to assess mortality following AMI in VHA were avail-
able only for calendar years 2004 through 2006. Second,
we were able to compare mortality in VHA and Medicare
using only administrative data because CMS does not col-
lect detailed clinical data on all patients with AMI.
Although there may have been unrecognized differences
in the way these data were collected, we believe that meas-
urement of vital status is consistent for the two popula-
tions. Third, there is ample evidence that reliance solely
on administrative data may fail to adequately adjust for
differences among patients treated in different systems of
care. [30] We think this is unlikely to have seriously
affected our analyses given that both the crude and fully
adjusted estimates of mortality were similar in the VA and
Medicare groups. Fourth, because the public release of
Medicare data is delayed, we were only able to make these
comparisons through 2005. Finally and most impor-
tantly, the inherent differences in the VA EPRP data and
the VHA and CMS administrative data sources led to
slightly different denominators and estimates of outcome.
The lower number of patients with AMI in the EPRP anal-
ysis is related to the fact that in a substantial minority of
patients who have a discharge diagnosis of AMI, careful
review of the medical record does not substantiate that
diagnosis. The differences in adjusted outcomes result, in
part, from the ability to adjust more completely for the
considerable burden of coexisting, chronic illness among
VA patients.
Conclusion
In summary, we found that mortality following AMI has
declined over the past four years in VA and that this
decline has been commensurate with that occurring in the
Medicare population.
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